Neonatal Medicine

  • 제25권4호
  • /
  • Pages.161-169
  • /
  • 2018
  • /
  • 2287-9412(pISSN)
  • /
  • 2287-9803(eISSN)
대한신생아학회 (The Korean Society of Neonatology)
권호 표지
DOI QR코드

DOI QR Code

Antenatal Corticosteroids and Clinical Outcomes of Preterm Singleton Neonates with Intrauterine Growth Restriction

  • Kim, Yoo Jinie (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine) ;
  • Choi, Sung Hwan (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine) ;
  • Oh, Sohee (Department of Biostatistics, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Sohn, Jin A (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine) ;
  • Jung, Young Hwa (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine) ;
  • Shin, Seung Han (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine) ;
  • Choi, Chang Won (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Ee-Kyung (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Han-Suk (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Beyong Il (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine) ;
  • Lee, Jin A (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine)
  • 투고 : 2018.07.17
  • 심사 : 2018.09.19
  • 발행 : 2018.11.30
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: We assessed the influence of antenatal corticosteroid (ACS) on the inhospital outcomes of intrauterine growth restriction (IUGR) infants. Methods: A retrospective study was conducted with singletons born at $23^{+0}$ to $33^{+6}weeks$ of gestation at Seoul National University Hospital from 2007 to 2014. We compared clinical outcomes between infants who received ACS 2 to 7 days before birth (complete ACS), at <2 or >7 days (incomplete ACS), and those who did not receive ACS in IUGR and AGA infants. Multivariate logistic regression using Firth's penalized likelihood was performed. Results: 304 neonates with 91 IUGR neonates were eligible. Among AGA neonates, mortality (adjusted odds ratio [aOR], 0.13; 95% confidence interval [CI], 0.02 to 0.78), hypotension within 7 postnatal days (aOR, 0.20; 95% CI, 0.06 to 0.64), and severe bronchopulmonary dysplasia (BPD) or death (aOR, 0.24; 95% CI, 0.07 to 0.77) were lower in complete ACS group after adjusting for pregnancy induced hypertension and uncontrolled preterm labor. Mortality (aOR, 0.18; 95% CI, 0.04 to 0.78), hypotension (aOR, 0.26; 95% CI, 0.09 to 0.70), and severe BPD or death (aOR, 0.33; 95% CI, 0.12 to 0.92) were also lower in the incomplete ACS group. Among IUGR infants, after adjusting for birth weight and 5-minute Apgar score, inhaled nitric oxide use within 14 postnatal days was lower in both complete ACS (aOR, 0.07; 95% CI, 0.01 to 0.67) and incomplete ACS (aOR, 0.04; 95% CI, 0.01 to 0.37) groups. Conclusion: ACS was not effective in reducing morbidities in IUGR preterm infants.

키워드

참고문헌

  1. Committee on Obstetric Practice. Committee opinion no. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2017;130:e102-9. https://doi.org/10.1097/AOG.0000000000002237
  2. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50:515-25.
  3. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017;3:CD004454.
  4. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994;12:1-24.
  5. Magann EF, Haram K, Ounpraseuth S, Mortensen JH, Spencer HJ, Morrison JC. Use of antenatal corticosteroids in special circumstances: a comprehensive review. Acta Obstet Gynecol Scand 2017;96:395-409. https://doi.org/10.1111/aogs.13104
  6. Ishikawa H, Miyazaki K, Ikeda T, Murabayashi N, Hayashi K, Kai A, et al. The effects of antenatal corticosteroids on short- and long-term outcomes in small-for-gestational-age infants. Int J Med Sci 2015;12:295-300. https://doi.org/10.7150/ijms.11523
  7. Melamed N, Pittini A, Barrett J, Shah J, Yoon EW, Lemyre B, et al. Antenatal corticosteroids and outcomes of small-for-gestational-age neonates. Obstet Gynecol 2016;128:1001-8. https://doi.org/10.1097/AOG.0000000000001674
  8. Kim WJ, Han YS, Ko HS, Park IY, Shin JC, Wie JH. Antenatal corticosteroids and outcomes of preterm small-for-gestationalage neonates in a single medical center. Obstet Gynecol Sci 2018;61:7-13. https://doi.org/10.5468/ogs.2018.61.1.7
  9. Torrance HL, Mulder EJ, Brouwers HA, van Bel F, Visser GH. Respiratory outcome in preterm small for gestational age fetuses with or without abnormal umbilical artery Doppler and/or maternal hypertension. J Matern Fetal Neonatal Med 2007;20:613-21. https://doi.org/10.1080/14767050701463662
  10. Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network. Am J Obstet Gynecol 2000;182(1 Pt 1):198-206. https://doi.org/10.1016/S0002-9378(00)70513-8
  11. van Stralen G, van der Bos J, Lopriore E, Te Pas AB, Bloemenkamp KW, Walther FJ, et al. No short-term benefits of antenatal corticosteroid treatment in severely preterm growth restricted fetuses: a case-control study. Early Hum Dev 2009;85:253-7. https://doi.org/10.1016/j.earlhumdev.2008.10.010
  12. Schaap AH, Wolf H, Bruinse HW, Smolders-De Haas H, Van Ertbruggen I, Treffers PE. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol 2001;97:954-60.
  13. Simchen MJ, Alkazaleh F, Adamson SL, Windrim R, Telford J, Beyene J, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004;190:296-304. https://doi.org/10.1016/j.ajog.2003.08.011
  14. Sharma D, Shastri S, Sharma P. Intrauterine growth restriction: antenatal and postnatal aspects. Clin Med Insights Pediatr 2016;10:67-83.
  15. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978;187:1-7. https://doi.org/10.1097/00000658-197801000-00001
  16. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529-34. https://doi.org/10.1016/S0022-3476(78)80282-0
  17. Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics 2010;125:e214-24. https://doi.org/10.1542/peds.2009-0913
  18. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants: 2013 update. Neonatology 2013;103:353-68. https://doi.org/10.1159/000349928
  19. Economides DL, Nicolaides KH, Linton EA, Perry LA, Chard T. Plasma cortisol and adrenocorticotropin in appropriate and small for gestational age fetuses. Fetal Ther 1988;3:158-64. https://doi.org/10.1159/000263348
  20. Torrance HL, Derks JB, Scherjon SA, Wijnberger LD, Visser GH. Is antenatal steroid treatment effective in preterm IUGR fetuses? Acta Obstet Gynecol Scand 2009;88:1068-73. https://doi.org/10.1080/00016340903176784
  21. Miller SL, Chai M, Loose J, Castillo-Melendez M, Walker DW, Jenkin G, et al. The effects of maternal betamethasone administration on the intrauterine growth-restricted fetus. Endocrinology 2007;148:1288-95. https://doi.org/10.1210/en.2006-1058
  22. McTernan CL, Draper N, Nicholson H, Chalder SM, Driver P, Hewison M, et al. Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab 2001;86:4979-83.
  23. Ozdemir H, Guvenal T, Cetin M, Kaya T, Cetin A. A placebocontrolled comparison of effects of repetitive doses of betamethasone and dexamethasone on lung maturation and lung, liver, and body weights of mouse pups. Pediatr Res 2003;53:98-103. https://doi.org/10.1203/00006450-200301000-00017
  24. Bertram C, Trowern AR, Copin N, Jackson AA, Whorwood CB. The maternal diet during pregnancy programs altered expression of the glucocorticoid receptor and type 2 11betahydroxysteroid dehydrogenase: potential molecular mechanisms underlying the programming of hypertension in utero. Endocrinology 2001;142:2841-53. https://doi.org/10.1210/endo.142.7.8238
  25. Morrison JL, Orgeig S. Antenatal glucocorticoid treatment of the growth-restricted fetus: benefit or cost? Reprod Sci 2009;16:527-38. https://doi.org/10.1177/1933719109332821
  26. Riskin-Mashiah S, Riskin A, Bader D, Kugelman A, Boyko V, Lerner-Geva L, et al. Antenatal corticosteroid treatment in singleton, small-for-gestational-age infants born at 24-31 weeks' gestation: a population-based study. BJOG 2016;123:1779-86. https://doi.org/10.1111/1471-0528.13723
  27. Ting JY, Kingdom JC, Shah PS. Antenatal glucocorticoids, magnesium sulfate, and mode of birth in preterm fetal small for gestational age. Am J Obstet Gynecol 2018;218(2S):S818-28. https://doi.org/10.1016/j.ajog.2017.12.227
  28. McGillick EV, Orgeig S, Williams MT, Morrison JL. Risk of respiratory distress syndrome and efficacy of glucocorticoids: are they the same in the normally grown and growth-restricted infant? Reprod Sci 2016;23:1459-72. https://doi.org/10.1177/1933719116660842
  29. Elimian A, Figueroa R, Spitzer AR, Ogburn PL, Wiencek V, Quirk JG. Antenatal corticosteroids: are incomplete courses beneficial? Obstet Gynecol 2003;102:352-5.
  30. Miller SL, Supramaniam VG, Jenkin G, Walker DW, Wallace EM. Cardiovascular responses to maternal betamethasone administration in the intrauterine growth-restricted ovine fetus. Am J Obstet Gynecol 2009;201:613.e1-8. https://doi.org/10.1016/j.ajog.2009.07.028
  31. Lai MY, Chu SM, Lakshminrusimha S, Lin HC. Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Pediatr Neonatol 2018;59:15-23. https://doi.org/10.1016/j.pedneo.2016.09.011
  32. Mitsiakos G, Kovacs L, Papageorgiou A. Are antenatal steroids beneficial to severely growth restricted fetuses? J Matern Fetal Neonatal Med 2013;26:1496-9. https://doi.org/10.3109/14767058.2013.789852